The macromolecular aggregate as a drug carrier

• Autorzy: Langer M. , Ugorski M.
• Języki publikacji: EN

Abstrakty

EN

Traditionally, a drug is expected to be biologically active and at the same time be able to ensure some sort of tissue or organ specificity. The latter property is necessary to avoid undesirable side effects when toxic drugs are being used. Such requirements are difficult to achieve only by changing the chemical formula of the drug. For these reasons, within the last few years a new pharmacological concept has been developed regarding delivery of biologically active compounds by the use of macromolecular aggregates. The purpose-specific design of macromolecular aggregates, able to deliver drugs to a desired location, is based on the assumption that different functions can be assigned to the separate chemical entities forming the aggregate. With the help of such an aggregate, the biologically active compound can be designed with solely its pharmacological potency in mind and without considering any limitations imposed by inaccurate delivery, such as undesired side effects. Specific molecules of the aggregate would ensure desired compound distribution within the organism. Furthermore, other molecules forming the aggregate should fulfill additional functions, e.g. protecting the drug from degradation. Additionally, aggregates formed from amphiphilic molecules should be capable of carrying drugs that are difficult to use as therapeutic agents due to low solubility in biological fluids (e.g. Taxol) or degradation (e.g. peptides, DNA). Such aggregates can be constructed from natural or/and synthetic compounds. Taken together, this creates possibilities of extending the spectrum of drug application and allows for the introduction of new technological modifications.

Słowa kluczowe

EN

macromolecular aggregate; drug carrier; drug delivery; liposome; pharmacology; biological activity; biologically active compound

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2000
• Tom: 05
• Numer: 4
• Opis fizyczny: p.433-440,fig.,ref.

Twórcy

autor

Langer M.

• Wroclaw University of Technology, Wyb.Wyspianskiego 27, 50-370 Wroclaw, Poland

autor

Ugorski M.

Bibliografia

• 1. Goodwin, J. T., Mao, B., Vidmar, T. J., Conradi, R. A. and Burton, P. S. Strategies towards predicting peptide cellular permeability from computed molecular descriptors. J. Peptide Res. 531 (999) 355-369.
• 2. Kramer, S. D. Absorption prediction from physicochemical parameters. Pharm. Sci. Technol. Today 2 (1999) 373-380.
• 3. Coonrod, A., Li, F. Q. and Horwitz. M. On the mechanism of DNA transfection: efficient gene transfer without viruses. Gene Ther. 4 (1997) 1313-1321.
• 4. Felgner, P. L. Nonviral strategies for gene therapy. Sci. Am. 276 (1997) 102-106.
• 5. Garcia, M., Alsina, M. A., Reig, F. and Haro I. Liposomes as vehicles for the presentation of a synthetic peptide containing an epitope of hepatitis A virus. Vaccine 18 (2000) 276-283.
• 6. Allen, T. M. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56 (1998) 747-756.
• 7. Janoff, A. S. Lipids, liposomes, rational drug design. J. Lab. Invest. 66 (1992) 655-658.
• 8. Lasic, D. D. Novel applications of liposomes. TIBTECH. 16 (1998) 307-321.
• 9. Mills, J. K. and Needham, D. Targeted drug delivery. Exp. Opin. Ther. Patents 9 (1999) 1499-1513.
• 10. Sharma, A. and Sharma, U. S. Liposomes in drug delivery: progress and limitations. Inter J. Pharmacol. 154 (1997) 123-140.
• 11. Boswell, G., Bekersky, I., Buell, D., Hiles, R. and Walsh, T. J. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B (AmBiosome) in rats. Antimicrob. Agents Chemother. 42 (1998) 263-368.
• 12. Mizushima, Y. Lipid microspheres (lipid emulsions) as a drug carrier – an overview. Adv. Drug Delivery Rev. 20 (1996) 113-115.
• 13. Velpandian, T., Gupta, S. K., Gupta, Y. K., Biswas, N. R. and Agarwal, H. C. Ocular drug targeting by liposomes and their corneal interactions. J. Microencapsulation 16 (1999) 243-250.
• 14. Szebeni, J. The interaction of liposomes with the complement system. Crit. Rev. Therapeutic Drug Carrier Systems 15 (1998) 57-88.
• 15. Arimoto, I., Matsumoto, C., Tanaka, M., Okuhira, K., Saito, H. and Handa, T. Surface composition regulates clearance from plasma and triolein lipolysis of lipid emulsions. Lipids 33 (1998) 773-779.
• 16. Cansell, M., Parisel, C., Jozefonicz, J. and Letourneur, D. Liposomes coated with chemically modified dextran interact with human endothelial cells. J. Biomed. Mater. Res. 44 (1999) 140-148.
• 17. Wu, N. Z., Da, D., Rudoll, T. L., Needham, D., Whorton, A. R. and W. Dewhirst, M. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53 (1993) 3765-3770.
• 18. Philips, W. T. Delivery of gamma-imaging agents by liposomes. Adv. Drug Deliv. Rev. 37 (1999) 13-32.
• 19. Oku, N. and Namba Y. Long-circulating liposomes. Crit. Rev. Ther. Drug Carrier Systems 11 (1994) 231-270.
• 20. Allen, T. M., d. Menezes, D. L., Hansen, C. B. and Moase E. H. Stealth liposomes for the targeting of drug in cancer therapy. Targeting Drugs 6 (1998) 61-75.
• 21. Barenholz, Y., Bolotin, E., Cohen, R. and Gabizon A. Sterically stabilized doxorubicin loaded liposomes (DOX-SL): from basic to the clinic. Phosphorus, Sulfur, and Silicon 109-110 (1996) 293-296.
• 22. Park, J. W., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. and Benz, C. C. Immunoliposomes for cancer treatment. Adv. Pharmacol. 40 (1997) 399-435.
• 23. Babai, I., Samira, S., Barebholz, Y., Zakay-Rones, Z. and Kedar E. A novel influenza subjunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II Induction of TH1 and TH2 responses in mice. Vaccine 17 (1999) 1239-1250.
• 24. Boswell, G. W., Buell, D. and Bekersky I. AmBiosome (liposomal Amphotericin B): a comparative review. J. Clinical Pharmacol. 38 (1998) 583-592.
• 25. Cef, B., Winterhalter, M., Frederik, P. M., Vallner, J. J. and Lasic, D. D. Stealth liposomes: from theory to product. Adv. Drug Deliv. Rev. 24 (1997) 165-211.